Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Drops By 7.1%

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the target of a significant decrease in short interest in March. As of March 15th, there was short interest totalling 432,000 shares, a decrease of 7.1% from the February 29th total of 464,800 shares. Approximately 1.6% of the shares of the company are short sold. Based on an average daily volume of 255,100 shares, the days-to-cover ratio is currently 1.7 days.

Institutional Trading of Werewolf Therapeutics

Several institutional investors have recently bought and sold shares of HOWL. Financial Perspectives Inc raised its stake in Werewolf Therapeutics by 80.0% during the fourth quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock worth $26,000 after acquiring an additional 3,000 shares in the last quarter. Certuity LLC acquired a new stake in shares of Werewolf Therapeutics during the 4th quarter worth about $39,000. Jane Street Group LLC acquired a new stake in shares of Werewolf Therapeutics during the 4th quarter worth about $45,000. Cubist Systematic Strategies LLC bought a new position in Werewolf Therapeutics during the 2nd quarter valued at about $54,000. Finally, Two Sigma Investments LP acquired a new position in Werewolf Therapeutics in the fourth quarter valued at about $56,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Stock Performance

HOWL opened at $6.38 on Tuesday. The company has a current ratio of 7.14, a quick ratio of 7.14 and a debt-to-equity ratio of 0.29. The firm’s fifty day moving average price is $6.16 and its two-hundred day moving average price is $4.05. Werewolf Therapeutics has a fifty-two week low of $1.57 and a fifty-two week high of $8.19.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its earnings results on Thursday, March 7th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.10. Werewolf Therapeutics had a negative net margin of 187.37% and a negative return on equity of 32.25%. The business had revenue of $1.50 million for the quarter, compared to analyst estimates of $2.75 million. On average, equities analysts anticipate that Werewolf Therapeutics will post -1.38 EPS for the current year.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.